<DOC>
	<DOCNO>NCT01448317</DOCNO>
	<brief_summary>Primary Objective : To assess safety tolerability ascend single dos subcutaneously ( SC ) administer alirocumab ( SAR236553/REGN727 ) Japanese healthy male subject . Secondary Objectives : - To assess pharmacodynamics effect single SC dose alirocumab serum low-density lipoprotein cholesterol ( LDL-C ) lipids apolipoproteins total cholesterol , high-density lipoprotein cholesterol ( HDL-C ) , non-high-density lipoprotein cholesterol , low-density lipoprotein cholesterol , Triglycerides , Apolipoprotein B , Apolipoprotein A1 Lipoprotein ( ) . - To assess Pharmacokinetic profile single SC dose alirocumab . - To assess immunogenicity single SC dose alirocumab .</brief_summary>
	<brief_title>Ascending Dose Study Safety Tolerability Alirocumab ( SAR236553/REGN727 ) Japanese Healthy Volunteers</brief_title>
	<detailed_description>4 sequential dose cohort . Single dose follow total observation period 15 week ( 106 day ) participant .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Healthy male subject , 20 65 year inclusive . Body weight 50.0 95.0 kg inclusive , body mass index 18.0 30.0 kg/mÂ² inclusive . Serum LDLC level &gt; 100 mg/dL Subject indicate use statin accord criterion Adult Treatment Panel ( ATP ) III Guidelines update 2004 Significant concomitant illness history significant illness cardiac , renal , neurological , endocrinological , dermatological , metabolic lymphatic disease , illness condition would adversely affect subject 's participation study . History presence drug alcohol abuse Smoking 5 cigarette equivalent 24 hour period . Any medication ( include St John 's Wort ) within 14 day inclusion within 5 time elimination halflife pharmacodynamic ( PD ) halflife drug , whichever long ; vaccination within last 28 day . Positive reaction follow test : hepatitis B surface ( HBs Ag ) antigen , antihepatitis B core antibody ( antiHBc Ab ) , antihepatitis C virus ( antiHCV ) antibody , human immunodeficiency virus ( HIV ) antigen antibody , syphilis . Elevated cholesterol due secondary cause hypothyroidism alcohol . Presence history drug hypersensitivity Initiation new exercise routine major change previous exercise routine within 4 week prior Screening . Initiation new diet major change previous diet within 4 week prior Screening . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>